These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31513823)

  • 1. The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes.
    Kim TH; Lee K; Park IB; Choi CS; Ahn TH; Lee DH
    Diabetes Res Clin Pract; 2019 Oct; 156():107832. PubMed ID: 31513823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
    Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
    J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
    Liu X; Men P; Wang Y; Zhai S; Liu G
    Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    J Diabetes Investig; 2018 Jul; 9(4):893-902. PubMed ID: 28950431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
    Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
    Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
    Kim SC; Glynn RJ; Liu J; Everett BM; Goldfine AB
    Acta Diabetol; 2014 Dec; 51(6):1015-23. PubMed ID: 25311055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies.
    Charoenngam N; Rittiphairoj T; Ponvilawan B; Ungprasert P
    Diabetes Metab Syndr; 2021; 15(1):249-255. PubMed ID: 33465685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus.
    Ali S; Fortune K; Masur J; Viscuse PV; Devitt ME; Dreicer R; Skelton WP
    Clin Genitourin Cancer; 2024 Oct; 22(5):102173. PubMed ID: 39191617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
    Mora-Rodríguez JM; Sánchez BG; Bort A; Díaz-Yuste A; Ballester-González R; Arrieta F; Sebastián-Martín A; Díaz-Laviada I
    Life Sci; 2024 Jan; 336():122292. PubMed ID: 38030058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
    Watanabe T; Temma Y; Okada J; Yamada E; Saito T; Osaki A; Shimda Y; Matsumoto S; Horiguchi K; Ishida E; Kondo Y; Okada K; Takamizawa T; Nakajima Y; Ozawa A; Okada S; Horigome M; Yamada M
    Endocr J; 2021 May; 68(5):599-603. PubMed ID: 33408313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
    Deacon CF
    Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome.
    Panda SP
    Endocr Metab Immune Disord Drug Targets; 2023; 23(2):179-187. PubMed ID: 35642117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.
    Bouchi R; Fukuda T; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Diabetes Metab Res Rev; 2018 Feb; 34(2):. PubMed ID: 29054111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus.
    Rai P; Zhao X; Sambamoorthi U
    J Pain Palliat Care Pharmacother; 2018; 32(2-3):90-97. PubMed ID: 30676844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Seong JM; Yee J; Gwak HS
    Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.